Otsuka Pharmaceutical Co., Ltd. v. Lupin Limited
Infringement action filed 10 Sep 2024 in the United States Court of Appeals for the Federal Circuit and closed 21 May 2026, with 3 patents asserted. Recorded basis of termination: appeal dismissed.
Case record
- Patents involved
- US10905694B2US8273735B2US8501730B2
- Case no.
- 24-2297
- Verdict cause
- Infringement action
- Court
- Fed. Cir.
- Court level
- Court of Appeals
- Case region
- District of Columbia
- Chief judge
- None recorded
- Trial level
- Appeal
- Filed – Closed
- 10 Sep 2024 – 21 May 2026
- Duration
- 618 days
- Basis of termination
- Appeal Dismissed
- Products & marks
- JYNARQUE® tolvaptan tablets in 15, 30, 45, 60, and 90 mg dosage · JYNARQUE® tolvaptan tablets
Check this patent against your own product
Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.
Get an FTO claim chart- 01Ranked prior artEvery hit source-linked
- 02Claim-level comparisonAgainst your own product
- 03Legal statusAcross 174 jurisdictions
Pharmaceutical solid preparation comprising benzazepines and production method thereof
The subject invention provides a novel pharmaceutical solid preparation that has superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients through the gastrointestinal tract. The pharmaceutical solid preparation of the present invention comprises:
- (a) 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzoazepine and/or salt thereof;
- (b) hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50% or greater; and
- (c) at least one member selected from the group consisting of carmellose, sodium carboxy methyl starch, crospovidone, and low substituted hydroxypropylcellulose with an average particle diameter of 30 to 70 μm, and a 90% cumulative particle diameter of 100 to 200 μm.
- Legal status
- Active
- Granted
- 2 Feb 2021
- Earliest priority
- 21 Jun 2007
- Est. expiry
- 7 Apr 2030
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- NAKAGAWA, SHINSUKE · SUZUKI, KAI · MUKAI, TADASHI
- Classification
- A61K31/55A61K9/20A61K9/16
- Prosecution counsel
- SUGHRUE MION, PLLC
- Examiner
- LUNDGREN, JEFFREY S
Process for preparing benzazepine compounds or salts thereof
This invention provides a process for preparing benzazepine compounds of the formula (1): wherein X1 is a halogen atom, R1 and R2 are a lower alkyl group, or salts thereof as well as intermediate benzoic acid compounds in high yield and high purity on industrial scale, which are useful as an intermediate for preparing a pharmaceutically active 2,3,4,5-tetrahydro-1H-1-benzazepine compound having vasopressin antagonistic activity.
- Legal status
- Active
- Granted
- 25 Sep 2012
- Earliest priority
- 2 Sep 2005
- Est. expiry
- 14 Aug 2028
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- TORISAWA, YASUHIRO · ABE, KAORU · MUGURUMA, YASUAKI · FUJITA, SHIGEKAZU · OGAWA, HIDENORI · UTSUMI, NAOTO · MIYAKE, MASAHIRO
- Classification
- C07D223/16
- Prosecution counsel
- FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER
- Examiner
- KIFLE, BRUCK
Also asserted in this case
1 moreThe docket lists 3 asserted patents. Full bibliographic detail, drawings and prosecution history for the remaining asserted patent are one query away in Eureka.
Parties of record
Otsuka Pharmaceutical Co., Ltd.
- Core tech
- A61K31/55A61K9/20A61K9/16C07D223/16
- Counsel
- Alicia Alexandra Rose Russo · John D. Murnane · Joshua Rothman · Megan S. Woodworth · Zachary L. Garrett
- Firm
- Venable LLP
Lupin Limited
- Core tech
- Not recorded
- Counsel
- Carol Pitzel Cruz · Jared C. Bunker · William R. Zimmerman
- Firm
- Knobbe Martens Olson & Bear, LLP
Counsel of record
| Attorney | For | Role |
|---|---|---|
| Alicia Alexandra Rose Russo | Otsuka Pharmaceutical Co., Ltd. | Plaintiff |
| John D. Murnane | Otsuka Pharmaceutical Co., Ltd. | Plaintiff |
| Joshua Rothman | Otsuka Pharmaceutical Co., Ltd. | Plaintiff |
| Megan S. Woodworth | Otsuka Pharmaceutical Co., Ltd. | Plaintiff |
| Zachary L. Garrett | Otsuka Pharmaceutical Co., Ltd. | Plaintiff |
| Carol Pitzel Cruz | Lupin Limited | Defendant |
| Jared C. Bunker | Lupin Limited | Defendant |
| William R. Zimmerman | Lupin Limited | Defendant |
Basis of termination
From the record · verbatim“THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED”
Case 24-2297 · Fed. Cir. · closed 21 May 2026
Related cases
Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.
Frequently asked questions
What is case 24-2297?
24-2297 is a patent infringement action brought by Otsuka Pharmaceutical Co., Ltd. against Lupin Limited, filed on 10 Sep 2024 in the United States Court of Appeals for the Federal Circuit. The case closed on 21 May 2026.
Which patents were asserted in 24-2297?
US10905694B2 (“Pharmaceutical solid preparation comprising benzazepines and production method thereof”), assigned to OTSUKA PHARMACEUTICAL CO., LTD., currently active; US8273735B2 (“Process for preparing benzazepine compounds or salts thereof”), assigned to OTSUKA PHARMACEUTICAL CO., LTD., currently active; US8501730B2 (“Process for preparing benzazepine compounds or salts thereof”), assigned to OTSUKA PHARMACEUTICAL CO., LTD.. The record also lists JYNARQUE® tolvaptan tablets in 15, 30, 45, 60, and 90 mg dosage and JYNARQUE® tolvaptan tablets.
How was case 24-2297 terminated?
The recorded basis of termination is appeal dismissed. The termination text reads: “THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED”
How long did case 24-2297 take?
618 calendar days, from filing on 10 Sep 2024 to closure on 21 May 2026.
Who were the attorneys and the judge in 24-2297?
Alicia Alexandra Rose Russo, John D. Murnane, Joshua Rothman, Megan S. Woodworth and Zachary L. Garrett are recorded as counsel for plaintiff Otsuka Pharmaceutical. Carol Pitzel Cruz, Jared C. Bunker and William R. Zimmerman appear for defendant Lupin.
Disclaimer. This page reproduces publicly available court docket data for case 24-2297 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.